HIV and HCV in DC: Epidemic Intricacies and Inclusive Approaches for Substance-Using Populations
Among persons living with HIV in the United States, an estimated 15 to 30% have HCV coinfection. For persons living with HIV who have HCV coinfection, liver-related morbidity and mortality is a prominent non-AIDS-related complication—up to 80 to 90% of liver-related deaths in persons living with HIV are attributable to HCV infection-and proper treatment remains a priority. This webinar will discuss HIV/HCV co-infection in DC, particularly among people who inject drugs, and evidence-based prevention and treatment strategies.
Learning Objectives
After completing this activity, the participant should be better able to:
- Discuss the epidemiology of HIV and HCV infections in populations of people who use drugs, in the District of Columbia.
- Outline established and emerging strategies to prevent infection in these individuals.
- Evaluate the approach to treatment of HIV and HCV in these individuals.
